title: Iodine-131MIBG SPECT/CT in neuroendocrine tumours: An institutional experience.
abstract: BACKGROUND
  Radiolabelled metaiodobenzylguanidine (MIBG) is commonly used for imaging of neuroendocrine tumors (NETs). The hybrid imaging with single photon emission computerized tomography/computerized tomography (SPECT/CT) co-registration can give that additional edge to this functional imaging modality.
  
  
  OBJECTIVE
  To study the additional value of (131)I-MIBG SPECT/CT scintigraphy in evaluation of NETs.
  
  
  METHODS
  We performed a retrospective study of the scintigraphic data of patients referred to our department for detection and follow-up of NETs from 2004 to 2008.
  
  
  METHODS
  Total number of studies were 370. Twenty-eight patients with equivocal findings on planar imaging had undergone additional SPECT/CT imaging. The contribution made by SPECT/CT imaging in these studies was analyzed.
  
  
  RESULTS
  In 27 of 28 cases, SPECT/CT provided vital additional information.
  
  
  CONCLUSIONS
  We concluded that SPECT/CT co-registration helps in exclusion, identification, and localization of primary and metastatic NETs. It differentiates physiological from pathological tracer distribution. It helps increase the confidence in reporting, especially in equivocal findings on planar imaging.
authors.affiliation: Department of Nuclear Medicine, Christian Medical College, Vellore, Tamil Nadu, India.
authors.forename: Priyanka
authors.initials: P
authors.lastname: Verma
authors.lastname: Chanadana
authors.forename: Julie
authors.initials: J
authors.lastname: Hephzibah
authors.forename: Nylla
authors.initials: N
authors.lastname: Shanthly
authors.forename: Regi
authors.initials: R
authors.lastname: Oommen
keywords: Radiolabelled metaiodobenzylguanidine; neuroendocrine tumors; single photon emission computerized tomography/computerized tomography
references.citation: Hematol Oncol Clin North Am. 2007 Jun;21(3):409-32; vii
references.pmid: 17548032
references.citation: Q J Nucl Med Mol Imaging. 2004 Jun;48(2):150-63
references.pmid: 15243410
references.citation: Eur J Nucl Med Mol Imaging. 2003 Dec;30(12):BP132-9
references.pmid: 14989227
references.citation: Endocr Rev. 2004 Jun;25(3):458-511
references.pmid: 15180952
references.citation: Nuklearmedizin. 2004 Oct;43(5):164-70
references.pmid: 15480505
references.citation: AJR Am J Roentgenol. 2008 Apr;190(4):1085-90
references.pmid: 18356459
references.citation: Semin Nucl Med. 1985 Apr;15(2):132-53
references.pmid: 3890187
references.citation: Semin Nucl Med. 2006 Jul;36(3):228-47
references.pmid: 16762613
references.citation: J Nucl Biol Med. 1991 Oct-Dec;35(4):207-15
references.pmid: 1823820
references.citation: Cancer Biother Radiopharm. 2004 Feb;19(1):129-34
references.pmid: 15068621
references.citation: Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):835-43
references.pmid: 12682789